Spotlights

AUXESIS PHARMA HOLDING AB (publ) is now a settlement company and started with Euroclear as the securities institution and Avanza Bank as the company’s Issuance

Östersund AUXESIS PHARMA HOLDING AB (publ) is in the establishment phase of pharmaceutical manufacturing in Östersund, Sweden.  In September 2023 the company will submit an

Protocol from The AUXESIS PHARMA HOLDING AB (publ) Annual General Meeting 2023 is now available for download in the Investor Hub.

AUXESIS PHARMA HOLDING (publ) Annual report /Årsredovisning and associated documents regarding the Annual Meeting is now available for download in the Investor Hub for investors.

The shareholders of AUXESIS PHARMA HOLDING AB (publ) with organization number 559195-6486 are hereby invited to the annual general meeting on June 16, 2023 at

New updated Pitch, Memorandum and Scenario Valuation 2023 for download. Auxesis Pharma Pitch 2023 Download here Auxesis Pharma Memorandum 2023 Download here Auxesis Pharma Scenario

Document regarding registration of sharholders deposit information is available for download in the Investor Hub.

Euroclear AUXESIS PHARMA HOLDING AB (publ) has now entered into an agreement with the issuance institute Avanza Sweden. All shareholders will be registered with Euroclear

Valuation AUXESIS 03/2023 Scenario valuation of the shares in AUXESIS PHARMA HOLDING AB (publ) prior to the launch of the company’s analgesic product ASA.P® is

Investor Invitation We are excited to invite you to our first Investor Forum monday the 30th of january at the Karolinska Institute, Huddinge, Sweden. On